As previously reported, Morgan Stanley downgraded Baker Hughes (BHI) to Equal Weight from Overweight. Analyst Ole Slorer sees increased risks around the Halliburton (HAL)/Baker Hughes deal and said the market seems to be underestimating the obstacles. Slorer said the deal could take another 5-6 months and face increased resistance from EC regulators, and is concerned any delay will accelerate Baker Hughes' deteriorating performance. The analyst thinks Baker Hughes shares could fall into the low $30's, if the deal fails.

Unusual total active option classes on open include: ImmunityBio (IBRX), Halliburton (HAL), Redfin (RDFN), Nokia (NOK), Matterport (MTTR), General Motors (GM), UPS (UPS), Philip Morris (PM), PepsiCo (PEP), and General Electric (GE).

Reports Q1 revenue $5.8B, consensus $5.67B. "Halliburton delivered solid first quarter results that again demonstrated the power of our strategy and the strength of our execution. Activity in North America recovered from fourth-quarter lows, and our international business delivered its 11th consecutive quarter of year-on-year growth," commented Jeff Miller, Chairman, President and CEO. "Our customers' multi-year activity plans across markets and asset types confirms my confidence in the strength and duration of this upcycle. Halliburton demonstrated its commitment to shareholder returns in the first quarter and repurchased $250 million of common stock - a solid start to the year and a good benchmark for our expectations going forward," concluded Miller.